Trade Reata Pharma - RETA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.29 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 172.17 |
| Open | 172.23 |
| 1-Year Change | 680.38% |
| Day's Range | 172.19 - 172.24 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 25, 2023 | 172.23 | 0.02 | 0.01% | 172.21 | 172.32 | 172.18 |
| Sep 22, 2023 | 172.17 | 0.00 | 0.00% | 172.17 | 172.19 | 172.11 |
| Sep 21, 2023 | 172.02 | -0.08 | -0.05% | 172.10 | 172.21 | 171.98 |
| Sep 20, 2023 | 172.07 | 0.10 | 0.06% | 171.97 | 172.07 | 171.97 |
| Sep 19, 2023 | 171.97 | 0.14 | 0.08% | 171.83 | 172.00 | 171.83 |
| Sep 18, 2023 | 171.90 | 0.08 | 0.05% | 171.82 | 171.93 | 171.60 |
| Sep 15, 2023 | 171.83 | -0.08 | -0.05% | 171.91 | 172.00 | 171.69 |
| Sep 14, 2023 | 171.92 | 0.05 | 0.03% | 171.87 | 171.93 | 171.84 |
| Sep 13, 2023 | 171.87 | 0.00 | 0.00% | 171.87 | 171.94 | 171.81 |
| Sep 12, 2023 | 171.83 | 1.44 | 0.85% | 170.39 | 171.91 | 170.08 |
| Sep 11, 2023 | 170.82 | 0.95 | 0.56% | 169.87 | 170.97 | 169.87 |
| Sep 8, 2023 | 170.15 | 0.58 | 0.34% | 169.57 | 170.23 | 169.57 |
| Sep 7, 2023 | 170.02 | 0.60 | 0.35% | 169.42 | 170.11 | 169.42 |
| Sep 6, 2023 | 169.51 | 0.34 | 0.20% | 169.17 | 169.60 | 169.05 |
| Sep 5, 2023 | 169.61 | 0.94 | 0.56% | 168.67 | 169.83 | 168.67 |
| Sep 1, 2023 | 169.13 | 0.31 | 0.18% | 168.82 | 169.36 | 168.82 |
| Aug 31, 2023 | 168.83 | 0.22 | 0.13% | 168.61 | 169.11 | 168.61 |
| Aug 30, 2023 | 168.53 | -0.22 | -0.13% | 168.75 | 169.03 | 168.53 |
| Aug 29, 2023 | 168.75 | -0.07 | -0.04% | 168.82 | 168.94 | 168.66 |
| Aug 28, 2023 | 168.77 | -0.10 | -0.06% | 168.87 | 169.17 | 168.71 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Reata Pharma Company profile
About Reata Pharmaceuticals Inc
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. The Company's lead programs are in rare forms of chronic kidney disease and rare neurological disease. The Company’s Bardoxolone methyl and omaveloxolone products are in development for the treatment of several forms of chronic kidney disease and a severe neurologic disorder called Friedreich’s ataxia, respectively. The Company’s Technologies include Nrf2 Activators and HSP90 Modulators. Nrf2 is a transcription factor that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. HSP90 Modulators developing a class of molecules that target pathways involved in the cellular stress response.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Reata Pharmaceuticals Inc revenues increased 27% to $11.5M. Net loss before extraordinary items increased 10% to $297.4M. Revenues reflect License and milestone increase of 71% to $8M. Higher net loss reflects Other Non Operating I/E increase from $21.9M to $46.7M (expense), General and administrative - Balancing increase of 44% to $65.8M (expense).
| Industry: | Biopharmaceuticals |
5320 Legacy Dr
PLANO
TEXAS 75024-3127
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com